FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and twelve months ended December 31, 2010. For the three months ended December 31, 2010, the Company reported a net loss of $10.0 million, or $0.36 per diluted share, compared to a net income of $1.1 million, or $0.05 per diluted share, for the same period in 2009. For the twelve months ended December 31, 2010, the Company reported a net loss of $33.9 million, or $1.38 per diluted share, compared to a net loss of $21.2 million, or $1.03 per diluted share, for the same period in 2009. The Company ended the year with $92.4 million of cash and cash equivalents and investments.
